Go to content
Qiagen N.V.

Qiagen N.V.

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 24 jul 2012 - 22:12
Statutaire naam Qiagen N.V.
Titel QIAGEN raises full-year 2012 outlook
Bericht Venlo, The Netherlands, July 24, 2012 – QIAGEN N.V. (NASDAQ: QGEN; Frank-furt Prime Standard: QIA) announced today that it has raised its full-year outlook for net sales and adjusted diluted EPS (earnings per share). These changes are based on the strong performance in the first half of 2012, as well as to take into account the acquisition of AmniSure and the initiative to enter next-generation sequencing. For the full year, total net sales are now expected to rise approximately 8-9% CER (previously 6-8% CER) on a mix of contributions from the acquisitions of Cellestis and Ipsogen in 2011 and AmniSure in May 2012, as well as the rest of the business. Full-year reported sales are expected to be adversely affected by currency movements against the U.S. dollar, QIAGEN’s reporting currency. Adjusted diluted earnings per share (EPS) are now expected to rise to approxi-mately $1.04-1.06 for full-year 2012 (previously $1.03-1.05). This takes into account approximately $0.01 per share of dilution for investments in the next-generation sequencing initiative, which included the acquisition of Intelligent Bio-Systems in 2012. These expectations do not take into account any further acquisitions that could be completed in 2012, the potential impact of share repurchases or the completion of any debt market transactions during the year.

Datum laatste update: 16 juni 2024